News
VYGR
6.04
+1.68%
0.10
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with a newly hired employe...
GlobeNewswire · 2d ago
BRIEF-Voyager Therapeutics Inc Files For Mixed Shelf Of Up To $300 Mln
Reuters · 11/08 15:54
Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 13:25
BRIEF-Voyager Therapeutics Reports Third Quarter Financial And Operating Results
Reuters · 11/08 12:37
Voyager Therapeutics Q3 EPS $0.45 Versus $(0.67) Loss Last Year, Sales $41.10M Versus $1.5M Prior Year
Benzinga · 11/08 12:11
Voyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07M
Seekingalpha · 11/08 12:08
Voyager Therapeutics Q3 2022 Earnings Preview
Seekingalpha · 11/07 18:03
Voyager Therapeutics's Earnings Outlook
Benzinga · 11/07 16:24
Notable earnings before Tuesday's open
Seekingalpha · 11/07 16:03
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will rep...
GlobeNewswire · 11/01 11:30
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?
Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/25 14:01
BRIEF-Voyager Therapeutics Presents Data Characterizing A Novel Cns Receptor And Demonstrating Low-Dose Potential Of Tracer Generated Capsid Families
BRIEF-Voyager Therapeutics Presents Data Characterizing A Novel Cns Receptor And Demonstrating Low-Dose Potential Of Tracer Generated Capsid Families
Reuters · 10/11 11:32
Pfizer In-Licenses Voyager Therapeutics' AAV Capsid For Rare Neurologic Disease Target
Benzinga · 10/04 15:34
Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Voyager Therapeutics (NASDAQ:VYGR) <a href="https://se...
Seekingalpha · 10/04 12:46
--Wedbush Adjusts Voyager Therapeutics Price Target to $4 From $3, Maintains Neutral Rating
--Wedbush Adjusts Voyager Therapeutics Price Target to $4 From $3, Maintains Neutral Rating
MT Newswires · 10/04 12:31
UPDATE: Voyager Eligible For Up To $290M In Associated Milestone Payments
Under the terms of the license option agreement, originally announced in October 2021, Voyager previously received a $30 million upfront payment and is entitled to receive a $10 million option exercise payment. Voyager
Benzinga · 10/04 11:03
Voyager Therapeutics Announces Pfizer License Of Next-Generation AAV Capsid For Rare Neurologic Disease Target
Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform Voyager eligible for up to $290 million in associated development, regulatory, and commercial
Benzinga · 10/04 11:02
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it wil...
GlobeNewswire · 10/03 11:00
Voyager Therapeutics, Inc. (NASDAQ:VYGR) most popular amongst individual investors who own 27% of the shares, institutions hold 26%
A look at the shareholders of Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) can tell us which group is most powerful. The...
Simply Wall St. · 10/03 10:26
More
Webull provides a variety of real-time VYGR stock news. You can receive the latest news about Voyager Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYGR
Voyager Therapeutics, Inc. is a gene therapy company, which is focused on developing treatments and platform technologies. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. It has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. It also focuses on tauopathies and indications in neuro-oncology.